Anticoagulation Therapy: Clinical Recommendations for a New Paradigm

James B. Groce III, PharmD, CACP
Professor, Campbell University College of Pharmacy and Health Sciences
Clinical Assistant Professor of Medicine, UNC
Clinical Pharmacy Specialist-Anticoagulation
Moses Cone Health System
Greensboro, NC
• The *faculty* reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  – James B. Groce III, PharmD
    • Consulting fees: Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb; Ortho-McNeill/Johnson & Johnson; sanofi-aventis
    • Fees for non-CME services received directly from a commercial interest or their agents: Boehringer Ingelheim Pharmaceuticals, Inc.; sanofi-aventis
Uses of Oral Anticoagulation

AF=atrial fibrillation.
DVT=deep vein thrombosis.
VTE=venous thromboembolism.
PE=pulmonary embolism.

AF=33%
Arterial=14%
DVT=17%
VTE=11%
Stroke=8%
Valves=3%
Other=4%

AF
Arterial
DVT
VTE
Stroke
PE
Valves
Other

National Disease and Therapeutic Index. June 2002.
Epidemiology of Atrial Fibrillation

- Estimated to affect >2.6 million Americans
  - Prevalence increasing as population ages
- Presence of AF confers a 5-fold higher risk for ischemic stroke
- Most common arrhythmia requiring hospitalization
  - 461,000 hospital discharges/year
  - Associated with >90,000 deaths/year
  - Risk for recurrent severe stroke is increased 2.4-fold in patients not treated with anticoagulants

Future of Atrial Fibrillation: ATRIA Study

Projected Number of Adults With AF in the US From 1995 to 2050


AF=atrial fibrillation.
Cardiovascular Deaths

Percentage Breakdown of US Deaths From CVD, 2001

CHD: 14%
Stroke: 4%
Hypertension: 7%
Heart Failure: 7%
Disease of the Arteries: 17%
Other: 51%

Source: National Center for Health Statistics.

CVD=cardiovascular disease.
CHD=coronary heart disease.
Incidence of Stroke According to Type of Atrial Fibrillation: Paroxysmal vs Sustained

Outcome of Stroke

• Leading cause of serious disability in the US
• 50-70% of stroke survivors regain functional independence
• 15-30% are permanently disabled
• 20% require institutional care at 3 months after onset

Outcome of Stroke With AF

- 1061 patients admitted with acute ischemic stroke
  - 20.2% had AF
- Bedridden state
  - With AF 41.2%  \[ P < 0.0005 \]
  - Without AF 23.7%
- Odds ratio for bedridden state following stroke due to AF: 2.23 (95% CI, 1.87-2.59; \( P < 0.0005 \))

Costs of Care in Atrial Fibrillation
Healthcare Payer Perspective

Treatment of AF Represents a Significant Burden

Distribution of Inpatient and Selected Outpatient Costs for Treating AF

- $6.65 billion (2005 US dollars) for AF treatment in the inpatient, emergency department, and hospital outpatient settings
- $2.93 billion (44%) for hospitalizations with a principal discharge diagnosis of AF
- $1.95 billion (29%) for the incremental inpatient cost of AF as a comorbid diagnosis
- $1.53 billion (23%) for outpatient treatment of AF
- $235 million (4%) for prescription drugs

Key Management Embolic Disease

Stroke Prevention

VTE Prevention

VTE Treatment

VTE=venous thromboembolism.
AF=atrial fibrillation.
FDA=Food and Drug Administration.
INR=international normalized ratio.
NDA=new drug application.
NVAF=non-valvular atrial fibrillation.
WHO=world health organization.
Warfarin in Eligible Patients: ATRIA Study

Patient Concerns About AF

- Stroke: 91.0%
- Death: 38.0%
- Major Bleeding: 13.0%
- Minor Side Effects: 9.0%
- Cost: 2.0%
- Inconvenience: 5.0%

AF=atrial fibrillation.

Basis for Physician Choice of Warfarin in Stroke Prophylaxis: *Survey of Family Physicians*

- Physicians not prescribing warfarin (vs physicians prescribing warfarin)
  - 3-6 times more likely to believe inadequate evidence exists to support use of warfarin
  - 4-6 times more likely to be concerned with risk of hemorrhage
  - Beliefs did not change despite introduction of scenario describing high stroke risk patients

- Study conclusion: physician reluctance to use warfarin associated with false understanding of risk–benefit ratio

Physician Questionnaire Results on AF and Warfarin

- No relationship between perceived benefits of warfarin and its use
- Perceived risk for hemorrhage strongly inversely associated with warfarin use ($P<0.001$)
- Estimated annual rates of warfarin-associated hemorrhage >10-fold higher than literature-based estimates
- Physician attitudes toward regret and risk aversion may impact treatment recommendations

AF=atrial fibrillation.
Physician Concerns About Warfarin for Stroke Prevention in AF

- 47% believe benefits of warfarin greatly outweigh risks
- 34% believe benefits of warfarin slightly outweigh risks
- 19% believe risks of warfarin outweigh benefits

Frequently Cited Contraindications

- Risk of Fall: 71%
- History of GI Bleed: 71%
- History of Non-CNS Bleed: 36%
- History of CV Hemorrhage: 25%


AF=atrial fibrillation.
Problems With Warfarin

- Delayed onset/offset
- Unpredictable dose response
- Narrow therapeutic range
- Drug–drug, drug–food interactions
- Problematic monitoring
- Slow reversibility

Ischemic Stroke and Intracranial Bleeding

- Ischemic stroke
- Intracranial bleeding

INR = international normalized ratio.

Quality of Anticoagulation

% of INRs in Range

0.00-1.49: 14.5%
1.50-1.99: 23.7%
2.00-2.99: 43.7%
3.00-3.49: 6.7%
3.50-4.99: 8.9%
≥5.00: 2.6%

% of Time INR Was Within Range

0.00-1.49: 12.2%
1.50-1.99: 26.3%
2.00-2.99: 46.8%
3.00-3.49: 7.4%
3.50-4.99: 5.7%
≥5.00: 1.7%

Cumulative Percentage


INR=international normalized ratio.
Quality of Warfarin Control
SPORTIF III and V

Halperin JL. Presented at the American Heart Association Annual Meeting. November 11, 2003; Orlando, FL.
Quality of Warfarin control
RE-LY

• Warfarin administered at: 1, 3, or 5 mg
• Warfarin adjusted locally to an INR of 2.0-3.0
  – INR testing at least once every 4 weeks
  – TTR monitored closely throughout study
  – TTR reported back through the course of the trial with advice for optimizing INR control
• Mean TTR achieved: 64%
• Effects of dabigatran vs warfarin more apparent in patients with lower levels of INR control

INR=international normalized ratio. RE-LY=randomized evaluation of long-term anticoagulant therapy. TTR=time in therapeutic range.

Incorporation of Existing and Evolving Therapies Into Treatment Guidelines
In patients with AF, including those with paroxysmal AF, who have had prior ischemic stroke, TIA, or systemic embolism, we recommend long-term anticoagulation with oral vitamin K antagonist, such as warfarin, targeted at an INR of 2.5 (range, 2.0-3.0) (Grade 1A).

ACCP=American College of Chest Physicians.
AF=atrial fibrillation.
INR=international normalized ratio.
TIA=transient ischemic attack.

In patients with AF, including those with paroxysmal AF, who have **two or more** of the following risk factors for future ischemic stroke, we recommend long-term* anticoagulation with an oral VKA (Grade 1A):

- Two or more of the following risk factors apply:
  1. Age >75 years
  2. History of hypertension
  3. Diabetes mellitus
  4. Moderately or severely impaired left ventricular systolic function and/or heart failure

*Lifelong unless a contraindication emerges.


ACCP=American College of Chest Physicians.
AF=atrial fibrillation.
VKA=vitamin K antagonist.
• In patients with AF, including those with paroxysmal AF, with only one of the risk factors listed below we recommend long-term* anticoagulation with an oral VKA (Grade 1A) or aspirin, at a dose of 75-325 mg/d (Grade 1B).

• For patients at intermediate risk, we suggest a VKA rather than aspirin (Grade 2A).
  – Risk factors:
    1. Age >75 years
    2. History of hypertension
    3. Diabetes mellitus
    4. Moderately or severely impaired left ventricular systolic function and/or heart failure

*Lifelong unless a contraindication emerges.


ACCP=American College of Chest Physicians.
AF=atrial fibrillation.
VKA=vitamin K antagonist.
In patients with AF, including those with paroxysmal AF, aged ≤75 years and with none of the other risk factors listed, we recommend long-term* aspirin, at a dose of 75-325 mg/d because of their low risk for stroke (Grade 1B).

- Risk factors:
  1. Age >75 years
  2. History of hypertension
  3. Diabetes mellitus
  4. Moderately or severely impaired left ventricular systolic function and/or heart failure

*Lifelong unless a contraindication emerges.


ACCP=American College of Chest Physicians.
AF=atrial fibrillation.
VKA=vitamin K antagonist.
Dabigatran is useful as an alternative to warfarin for the prevention of stroke and systemic thromboembolism in patients with paroxysmal to permanent AF and risk factors for stroke or systemic embolization who do not have a prosthetic heart valve or hemodynamically significant valve disease, severe renal failure (creatinine clearance 15 mL/min), or advanced liver disease (impaired baseline clotting function) (Class I Recommendation; Level of Evidence: B).

ACCF=American College of Cardiology Foundation.
AHA=American Heart Association.
HRS=Heart Rhythm Society.
AF=atrial fibrillation.

Anticoagulation Clinics

- Pharmacist-managed anticoagulation services are the most widely utilized case management strategies for patients with AF
- Clinics provide coordinated clinical infrastructures for
  - Patient education
  - Therapeutic monitoring
  - Dose adjustment to keep warfarin within its narrow therapeutic window

AF=atrial fibrillation.
Future of Anticoagulation Clinics in the Era of New Oral Anticoagulants

- DTIs have many potential advantages over warfarin, including predictable therapeutic effect at fixed doses and limited drug–drug interactions¹
  - These features may allow for routine therapy without monitoring and associated dosage adjustments
- DTIs present both an opportunity and a threat to anticoagulation service providers²
- Traditional anticoagulation monitoring services will have to retool if they are to remain relevant²

1. Ansell J. Hematology. 2010;221-228.

DTI=direct thrombin inhibitor.
Essential Elements of Optimal Anticoagulation
Did Not Change for 60 Years…

• The successful use of (anticoagulation) depends on an “essential triad” which includes a
  – Vigilant clinician
  – Cooperative (well educated) patient
  – Readily available and reliable laboratory

• If these factors are present, continuous use of anticoagulation is practical…and effective; if not, the use of the drug is dangerous…

Aske JM, Cherry CB. *J Am Med Assoc.* 1950;144:97-100.
...However, the Arrival of New Oral Anticoagulants Will Impact Plan Policies and Processes

- Availability of new oral anticoagulants will impact the way plans think about care delivery and management for patients with atrial fibrillation
  - Clinical management including guidelines/algorithms, patient education, monitoring, etc.
  - Clinical infrastructure and staffing
  - Cost management including cost-sharing, benefit design, formulary structure, etc.

What Is the Role of Guidelines?

- Will guidelines be product-specific?
- Will guidelines allow flexibility in management?
Will Plans Restrict Access to New Oral Anticoagulants?

• Is there a reason to restrict the use of the new oral anticoagulants?
  – Step therapy through warfarin?
  – Prior authorization for an atrial fibrillation indication?

• Financial risk is high for use that has not been approved
What Is the Anticipated Impact of Future Indications and Additional New Therapies?
## Anticoagulant Pipeline and Anticipated Indications (Projected)

<table>
<thead>
<tr>
<th>MOA</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rivaroxaban</td>
<td>Xa</td>
<td>Hip &amp; knee</td>
<td>Med ill</td>
<td></td>
<td>VTE</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AF</td>
<td>ACS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dabigatran</td>
<td>DTI</td>
<td>AF</td>
<td>Hip &amp; knee</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apixaban</td>
<td>Xa</td>
<td></td>
<td>Med ill, VTE</td>
<td></td>
<td>ACS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(2Q)</td>
<td>AF (3Q)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hip &amp; knee (4Q)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Betrixaban</td>
<td>Xa</td>
<td>Hip &amp; knee</td>
<td></td>
<td></td>
<td>AF</td>
</tr>
<tr>
<td>Edoxaban</td>
<td>Xa</td>
<td></td>
<td></td>
<td>AF, VTE</td>
<td></td>
</tr>
<tr>
<td>Ticagrelor</td>
<td>ADP</td>
<td>ACS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tra-Sch</td>
<td>TRA</td>
<td>ACS</td>
<td>ACS</td>
<td>ACS/NSTEMI</td>
<td></td>
</tr>
<tr>
<td>Clopidogrel*</td>
<td>ADP</td>
<td>AF</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ACS=acute coronary syndrome. ADP=adenosine diphosphate. AF=atrial fibrillation. DTI=direct thrombin inhibitor. MOA=mechanism of action. NSTEMI=non-ST segment elevation myocardial infarction. TRA=thrombin-receptor antagonists. VTE=venous thromboembolism. Xa=direct factor Xa inhibitors.


New Oral Anticoagulants Have the Potential to Become a Replacement for Warfarin

- Given the challenges associated with warfarin, an oral anticoagulant is especially attractive.
- Features of oral anticoagulants that may be associated with greater adherence include:
  - Do not require monitoring.
  - Fewer adverse effects, drug-drug, and drug-food interactions.
- Improved adherence may reduce the risk of subtherapeutic INR and may lead to better treatment outcomes and possibly lower costs.

Disadvantages of New Oral Anticoagulants

• Short half-life of oral anticoagulants makes adherence important
• Reduced monitoring may deny physician the opportunity for patient education and the earlier detection of problems
  – Denies practitioner the opportunity to tailor the intensity of anticoagulant therapy for patient-specific factors
• Acquisition costs associated with oral anticoagulants will be greater than for warfarin
  – Payers may erect barriers to access
  – Cost-sharing may decrease adherence

Ansell J. Hematology. 2010;221-228.
Formulary Management Considerations and Managed Care Issues

- Preferred agents
  - Collaborate with providers
  - Guidelines?
- Contracting opportunities?
- Limit to data and indications
  - Step edits
  - Prior authorizations
- PMPM and budgeting with employers
  - Direct current costs vs cost offsets

Ansell J. Hematology. 2010;221-228. PMPM=per member, per month.
Impact of New Agents on Current and Future Guidelines and Protocols

- “These drugs will change the paradigm in stroke prevention for atrial fibrillation in the United States, and that is a very, very good thing”
- “…they are very relevant to managed care organizations”
- Their approval “should change the way health care organizations think about health care delivery for patients with atrial fibrillation”